Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Historical Prospective Study Evaluating the Impact of the Marketing of ALTUVOCT® (Efanesoctocog Alfa) on the Prophylactic Outpatient Management of Severe and Oderate Hemophilia A (FVIII:C < 3 IU/dL)

NCT07830693 is registered in ClinicalTrials.gov with Nantes University Hospital as lead sponsor.

NCT NCT07830693
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07830693 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Historical Prospective Study Evaluating the Impact of the Marketing of ALTUVOCT® (Efanesoctocog Alfa) on the Prophylactic Outpatient Management of Severe and Oderate Hemophilia A (FVIII:C < 3 IU/dL)
Lead sponsor
Nantes University Hospital
Phase
Observational
Overall status
Not yet recruiting
Start date
January 1, 2027
Completion date
December 31, 2028
Enrollment
553 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

hemophilia a patient